Proteins and Peptides

15 Nov 2016 ERYTECH Announces Withdrawal of Its European Marketing Authorization Application for GRASPA for Acute Lymphoblastic Leukemia and Prepares for Resubmission
14 Nov 2016 Stealth BioTherapeutics Initiates Phase 1 Study of Elamipretide in Dry Age-Related Macular Degeneration
14 Nov 2016 AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
14 Nov 2016 Catalyst Biosciences Announces Positive Preclinical Data with Subcutaneous Dosing of Coagulation Factor IX at ASH Annual Meeting
14 Nov 2016 European Commission Approves Parsabiv™ (etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adults On Hemodialysis
14 Nov 2016 STADA receives “positive opinion” from the EMA for teriparatide biosimilar
11 Nov 2016 Novo Nordisk receives positive opinion from the European regulatory authorities for Fiasp® (fast-acting insulin aspart) for the treatment of diabetes
11 Nov 2016 Sanofi Receives CHMP Recommendation for Approval of SuliquaTM in the EU
10 Nov 2016 Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee
10 Nov 2016 Novo Nordisk submits application in the EU for including data from the two SWITCH trials in Tresiba® label
10 Nov 2016 Amgen Announces Collaboration With Janssen To Co-Fund Studies With KYPROLIS® (Carfilzomib) And DARZALEX® (Daratumumab) In Patients With Multiple Myeloma
10 Nov 2016 Halozyme Announces Broad Clinical Collaboration Agreement To Evaluate PEGPH20 And Tecentriq In Up To Eight Tumor Types
10 Nov 2016 Nektar Therapeutics Presents New Clinical Data from Ongoing Phase 1 Dose-Escalation Study of NKTR-214 at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
09 Nov 2016 RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259
08 Nov 2016 The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
08 Nov 2016 Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients
06 Nov 2016 Rhythm Presents Positive Initial Data for Setmelanotide in LepR Deficiency Obesity
04 Nov 2016 Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease
04 Nov 2016 Nutrinia Announces First Patient Enrolled in Phase III Trial
04 Nov 2016 Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency
04 Nov 2016 Atox Bio Announces Independent Safety Monitoring Committee Recommendation to Continue Phase 3 Study Of AB103 In Necrotizing Soft Tissue Infections
04 Nov 2016 Revance Announces Initiation of Phase 2 Trial of RT002 Injectable to Treat Plantar Fasciitis
02 Nov 2016 Spyryx Biosciences Presents Data at NACFC on SPX-101 Demonstrating Efficacy, Safety, and Stability in Animal Models
02 Nov 2016 Bremelanotide Meets Co-Primary Endpoints in Palatin's Phase 3 Trials for Hypoactive Sexual Desire Disorder
28 Oct 2016 The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top